Develops RNA-editing genetic medicines, using oligonucleotides to repair or alter proteins for people with rare and common diseases.
10-K for FY2025, filed Mar 12, 2026We are a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing…View ↗
Mammals and other lower species like cephalopods have an endogenous process of modifying single nucleosides on RNA, referred to as RNA…View ↗
As opposed to gene silencing with small interfering RNA, or siRNA, or antisense oligonucleotide, or ASO, gapmers, where oligonucleotides…View ↗
Korro has no approved products or product-sale revenue. It earned collaboration revenue from Novo Nordisk under a research collaboration and license agreement; the agreement combines licensing with research work, with payment tied to the license and work performed over time.
10-K for FY2025, filed Mar 12, 2026We do not have any development candidates approved for sale and have not generated any revenue from product sales. We will not generate…View ↗
We have not generated any revenue from product sales, and do not expect to generate any revenue from the sale of products in the near…View ↗
Licenses of intellectual property, or IP: If the license to the Company’s IP is determined to be distinct from the other performance…View ↗
$6.4M
10-K for FY2025, filed Mar 12, 2026
$6.4M ↗
Novo Nordisk is the named research collaborator and licensee; the reports do not describe how customers buy.
10-K for FY2025, filed Mar 12, 2026
No. It lost $117.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$17.5MView ↗
8-K, filed Aug 19, 2026
On August 19, 2026, Korro Bio, Inc., or Korro, announced a submission to the Australian Alfred Health Human Ethics Committee to initiate a…View ↗
8-K, filed Aug 6, 2026
KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical…View ↗
Shrinking. Revenue fell 54% in 4 years, from $14M in FY2021 to $6.4M in FY2025, about 18% a year.
From regenerative medicine to RNA editing
The older report described small-molecule medicines that activate progenitor cells, with remyelination for multiple sclerosis as the focus. The latest report describes oligonucleotide medicines that edit RNA to repair or alter proteins across rare and common diseases.
10-K for FY2022, filed Mar 10, 2023 10-K for FY2025, filed Mar 12, 2026
Competes with AIRNA, Beam Therapeutics, Prime Medicine, ProQR, Tessera Therapeutics, Verve Therapeutics, Wave Life Sciences, YolTech Therapeutics, Edigene, and Shape Therapeutics
10-K for FY2025, filed Mar 12, 2026The pharmaceutical and biotechnology industries, including the gene therapy and gene editing fields, are characterized by rapidly advancing…View ↗
Loading...